Target Name: FFAR4
NCBI ID: G338557
Review Report on FFAR4 Target / Biomarker Content of Review Report on FFAR4 Target / Biomarker
FFAR4
Other Name(s): GPR129 | free fatty acid receptor 4 | G-protein coupled receptor GT01 | G protein-coupled receptor 129 | G-protein coupled receptor 120 | Omega-3 fatty acid receptor 1 | PGR4 | G-protein coupled receptor 129 | G-protein coupled receptor PGR4 | Free fatty acid receptor 4, transcript variant 1 | G protein-coupled receptor 120 | FFAR4 variant 1 | G protein-coupled receptor PGR4 | Free fatty acid receptor 4 | omega-3 fatty acid receptor 1 | G-protein-coupled receptor GT01 | GT01 | GPR120 | O3FAR1 | Free fatty acid receptor 4 (isoform GPR120-L) | FFAR4_HUMAN | BMIQ10

FFAR4: A GPCR Involved in Cellular Signaling and Potential Drug Target

G protein-coupled receptors (GPCRs) are a family of transmembrane proteins that play a crucial role in cellular signaling. GPCRs are involved in a wide range of physiological processes, including sensory perception, neurotransmission, and hormone signaling. GPR129, also known as FFAR4, is a GPCR that is expressed in many tissues and is involved in several cellular processes.

FFAR4 is a protein that is 129 amino acids long and has a molecular weight of 14.5 kDa. It is a GPCR that is expressed in many tissues, including the brain, heart, and kidneys. It is involved in several cellular processes, including neurotransmission, sensory perception, and hormone signaling.

Drugs that target GPCRs, such as FFAR4, can be used to treat a wide range of diseases. For example, GPCRs are involved in the transmission of sensory information from the brain to the rest of the body. Drugs that target GPCRs can be used to treat disorders that are characterized by the disruption of this signaling system.

FFAR4 is also a potential biomarker for several diseases. The disruption of GPCRs has been implicated in a wide range of diseases, including neurological and psychiatric disorders. Drugs that target GPCRs, including FFAR4, may be used to treat these disorders.

Targeting GPCRs:

GPCRs are a family of transmembrane proteins that are involved in a wide range of cellular signaling processes. They are expressed in many tissues and are involved in the transmission of sensory information from the brain to the rest of the body.

Drugs that target GPCRs can be used to treat a wide range of diseases. For example, GPCRs are involved in the transmission of sensory information from the brain to the rest of the body. Drugs that target GPCRs can be used to treat disorders that are characterized by the disruption of this signaling system.

FFAR4 is a GPCR that is expressed in many tissues. It is involved in several cellular processes, including neurotransmission, sensory perception, and hormone signaling. Drugs that target FFAR4 may be used to treat disorders that are characterized by the disruption of these signaling systems.

Biomarker:

FFAR4 is also a potential biomarker for several diseases. The disruption of GPCRs has been implicated in a wide range of diseases, including neurological and psychiatric disorders.

Drugs that target GPCRs, including FFAR4, may be used to treat these disorders. For example, drugs that target GPCRs have been shown to be effective in treating symptoms of depression and anxiety.

Conclusion:

In conclusion, FFAR4 is a GPCR that is involved in several cellular processes, including neurotransmission, sensory perception, and hormone signaling. It is a potential drug target and may be used to treat a wide range of diseases. The disruption of GPCRs has been implicated in a wide range of disorders, including neurological and psychiatric disorders. Further research is needed to fully understand the role of FFAR4 in cellular signaling and its potential as a drug target.

Protein Name: Free Fatty Acid Receptor 4

Functions: G-protein-coupled receptor for long-chain fatty acids (LCFAs) with a major role in adipogenesis, energy metabolism and inflammation. Signals via G-protein and beta-arrestin pathways (PubMed:22282525, PubMed:24742677, PubMed:27852822, PubMed:24817122, PubMed:22343897). LCFAs sensing initiates activation of phosphoinositidase C-linked G proteins GNAQ and GNA11 (G(q)/G(11)), inducing a variety of cellular responses via second messenger pathways such as intracellular calcium mobilization, modulation of cyclic adenosine monophosphate (cAMP) production, and mitogen-activated protein kinases (MAPKs) (PubMed:27852822, PubMed:22343897, PubMed:22282525, PubMed:24742677). After LCFAs binding, associates with beta-arrestin ARRB2 that acts as an adapter protein coupling the receptor to specific downstream signaling pathways, as well as mediating receptor endocytosis (PubMed:22282525, PubMed:24817122). In response to dietary fats, plays an important role in the regulation of adipocyte proliferation and differentiation (By similarity). Acts as a receptor for omega-3 polyunsaturated fatty acids (PUFAs) at primary cilium of perivascular preadipocytes, initiating an adipogenic program via cAMP and CTCF-dependent chromatin remodeling that ultimately results in transcriptional activation of adipogenic genes and cell cycle entry (By similarity). Induces differentiation of brown adipocytes probably via autocrine and endocrine functions of FGF21 hormone (By similarity). Activates brown adipocytes by initiating intracellular calcium signaling that leads to mitochondrial depolarization and fission, and overall increased mitochondrial respiration (By similarity). Consequently stimulates fatty acid uptake and oxidation in mitochondria together with UCP1-mediated thermogenic respiration, eventually reducing fat mass (By similarity). Regulates bi-potential differentiation of bone marrow mesenchymal stem cells toward osteoblasts or adipocytes likely by up-regulating distinct integrins (By similarity). In response to dietary fats regulates hormone secretion and appetite (By similarity). Stimulates GIP and GLP1 secretion from enteroendocrine cells as well as GCG secretion in pancreatic alpha cells, thereby playing a role in the regulation of blood glucose levels (By similarity). Negatively regulates glucose-induced SST secretion in pancreatic delta cells (By similarity). Mediates LCFAs inhibition of GHRL secretion, an appetite-controlling hormone (By similarity). In taste buds, contributes to sensing of dietary fatty acids by the gustatory system (By similarity). During the inflammatory response, promotes anti-inflammatory M2 macrophage differentiation in adipose tissue (By similarity). Mediates the anti-inflammatory effects of omega-3 PUFAs via inhibition of NLRP3 inflammasome activation (PubMed:23809162). In this pathway, interacts with adapter protein ARRB2 and inhibits the priming step triggered by Toll-like receptors (TLRs) at the level of TAK1 and TAB1 (By similarity). Further inhibits the activation step when ARRB2 directly associates with NLRP3, leading to inhibition of pro-inflammatory cytokine release (PubMed:23809162). Mediates LCFAs anti-apoptotic effects (By similarity)

The "FFAR4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FFAR4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

FGA | FGB | FGD1 | FGD2 | FGD3 | FGD4 | FGD5 | FGD5-AS1 | FGD5P1 | FGD6 | FGF1 | FGF10 | FGF10-AS1 | FGF11 | FGF12 | FGF12-AS2 | FGF13 | FGF13-AS1 | FGF14 | FGF14-AS1 | FGF14-AS2 | FGF14-IT1 | FGF16 | FGF17 | FGF18 | FGF19 | FGF2 | FGF20 | FGF21 | FGF22 | FGF23 | FGF3 | FGF4 | FGF5 | FGF6 | FGF7 | FGF7P3 | FGF7P5 | FGF7P6 | FGF8 | FGF9 | FGFBP1 | FGFBP2 | FGFBP3 | FGFR1 | FGFR1OP2 | FGFR2 | FGFR3 | FGFR3P1 | FGFR4 | FGFRL1 | FGG | FGGY | FGL1 | FGL2 | FGR | FH | FHAD1 | FHDC1 | FHF Complex | FHIP1A | FHIP1B | FHIP2A | FHIP2B | FHIT | FHL1 | FHL2 | FHL3 | FHL5 | FHOD1 | FHOD3 | FIBCD1 | FIBIN | FIBP | Fibrinogen | Fibroblast growth factor (FGF) | Fibroblast Growth Factor Receptor (FGFR) | Fibronectin Type III Domain | FICD | FIG4 | FIGLA | FIGN | FIGNL1 | FIGNL2 | FILIP1 | FILIP1L | FILNC1 | FIP1L1 | FIRRE | FIS1 | FITM1 | FITM2 | Five friends of methylated CHTOP complex | FIZ1 | FJX1 | FKBP10 | FKBP11 | FKBP14 | FKBP15 | FKBP1A